The researchers behind the new AI system explained IPF is a good candidate for this type of technology, since existing ...

Antony says there is a critical need for a better predictive model for IPF. Animal models of the disease are disappointing, and more traditional two dimensional cellular models are insufficient.

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those ...

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Comp ...

Tested on cellular systems and animal models, ... In February 2021, Insilico nominated INS018_055 as a preclinical candidate for the treatment of IPF, ...

Inhibiting PDE4B is a promising approach in IPF, the group asserted, based on studies in animal models and human tissues in vitro. Inflammation, in which PDE4 enzymes are heavily involved, is seen ...

--Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that it has begun screening patients for suitability for enrolment in its Phase 2 ...

One mid-stage study is going to use this LPA1R antagonist drug for the treatment of patients with IPF, and then the other mid-stage study will use this very same drug for the treatment of patients ...

--Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has reached 50% of its enrollment target for its Phase 2 idiopathic pulmonary ...